{"schema_version":"1.0","canonical_url":"https://patentable.app/patents/US-9738933","patent":{"patent_number":"US-9738933","title":"RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS","assignee":null,"inventors":[],"filing_date":"2013-12-05T00:00:00.000Z","publication_date":"2017-08-22T00:00:00.000Z","cpc_codes":["C12Q","G01N","G01N","C12Q","C12Q","G01N","G01N"],"num_claims":8,"abstract":"Disclosed herein is a method of using erythroid expression levels of RNF41 as a predictive biomarker for responsiveness to lenalidomide (LEN) in patients with non-del(5q) MDS."},"analysis":{"summary":null,"layman_explanation":null,"technical_analysis":null,"business_analysis":null,"faqs":null,"topics":[],"tech_cluster":null},"seo":{"title":"RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS","description":"Disclosed herein is a method of using erythroid expression levels of RNF41 as a predictive biomarker for responsiveness to lenalidomide (LEN) in patients with non-del(5q) MDS.","keywords":[]},"attribution":{"source":"Patentable","source_url":"https://patentable.app","canonical_url":"https://patentable.app/patents/US-9738933","license":"CC-BY-4.0-like","license_terms":"AI-generated analysis on this page (summary, layman_explanation, technical_analysis, business_analysis, faqs) may be reused with attribution and a visible link back to the canonical URL above. Patent abstracts, claims, and bibliographic data are USPTO public domain.","required_link":"https://patentable.app/patents/US-9738933","citation_suggestion":"Patentable. \"RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS\" (US-9738933). https://patentable.app/patents/US-9738933","copyright_holder":"Nomic Interactive Technology LLC"},"links":{"html":"https://patentable.app/patents/US-9738933","json":"https://patentable.app/api/llm-context/US-9738933","site":"https://patentable.app","llms_txt":"https://patentable.app/llms.txt"},"generated_at":"2026-06-06T08:03:05.741Z"}